Short answer
Inhibikase Therapeutics, Inc. (IKT) filed its Q2 2026 10-Q quarterly report on Aug 11, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $0 with net income of −$20M.
Q2 2026 key financials · XBRL
- Revenue
- $0
- Net income
- −$20M
- −97.6% YoY · −19.6% QoQ
- EPS (diluted)
- −$0.11
- +0.0% YoY · −10.0% QoQ
Source: XBRL data from the Inhibikase Therapeutics, Inc. (IKT) Q2 2026 10-Q on SEC EDGAR. USD.
Inhibikase Therapeutics, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New regulatory risk: BIOSECURE Act and WuXi AppTec’s June 2026 Section 1260H designation
- Manufacturing concentration: STA Pharmaceutical Hong Kong supplies IKT-001 drug substance and drug product
- Supply-chain disruption: Potential STA designation could require costly, time-consuming manufacturing transition
- Clinical-development risk: Proposed restrictions on China-based clinical data could delay trials or increase costs
- Operational risk: Manufacturing deviations may reduce yields, cause defects, or disrupt clinical-trial supply
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Inhibikase Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.